MACROGENICS INC (MGNX): Completion of Acquisition or Disposition of Assets
MACROGENICS INC (MGNX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-99.2 3 exhibit99-2proforma.htm EX-99.2 Document Exhibit 99.2 MACROGENICS, INC. UNAUDITED CONSOLIDATED PRO FORMA FINANCIAL INFORMATION Effective as of June 30, 2026, MacroGenics, Inc. (the “Company”) completed the previously announced sale (the “Closing”) of certain assets and
How this was made
The 30-second read
Why it matters
The deal transfers CDMO operations to Bora and provides $122.5M upfront with potential additional $5M tied to manufacturing milestones and professional development services in 2027–2028; pro forma removes CDMO-related contract manufacturing revenue and manufacturing costs.
Market read
Traders can update models for the removal of contract manufacturing revenue/costs and assess whether any contingent consideration could re-emerge as a future earnings swing factor.
What to watch
Unclear whether the transaction qualifies as a discontinued operation under ASC 205-20; classification could affect how investors interpret future earnings quality and segment comparability.
Background
MacroGenics previously announced an asset sale of GMP manufacturing operations (including CDMO business) and related warehouse operations, excluding research assets.
Ticker impact
MacroGenics completed the sale of GMP manufacturing/CDMO assets to Bora for $122.5M plus up to $5M contingent milestone payments.
Near-term trading likely modest unless investors reprice the earnings impact of removing CDMO operations and the likelihood of contingent consideration.
The filing is a primary disclosure of transaction completion and consideration terms, but it provides limited forward guidance; pro forma shows CDMO-related revenue/cost lines removed and contingent consideration treated as remote.
Market effects
Signals ongoing portfolio reshaping among biotech CDMO/biomanufacturing operators, potentially affecting perceived demand for outsourced GMP capacity.
Limited direct regional impact; transaction involves facilities in Maryland but is an asset transfer rather than a new build.
Cross-border buyer (Taiwan) may reinforce international consolidation in biomanufacturing services.
Counterpoint
Because management deems contingent consideration probability remote, the market may already discount most upside; stock reaction could be muted despite the headline cash proceeds.
Key entities
- companyMacroGenics, Inc.
Seller; completed the asset disposition of GMP manufacturing/CDMO operations and issued pro forma financials in an 8-K.
- companyBora Pharmaceuticals Co., Ltd.
Purchaser under the asset purchase agreement; assumed responsibility for CDMO operations.
- companyBora Biologics USA, LLC
Purchaser entity (Delaware LLC) participating in the transaction.
